Is this you?
Request access for Pioneer Research with your @pioneerresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Pioneer Research
Unclaimed profileHybrid · South Florida (Miami) · ~5-7 sites
Intera lens
ICP 5Lift (cardio sample) 0.71Recruit soph 0.29
Quality Scorecard (1–100)
Overall70Recruit58Ops78Sponsor76Ther70
Performance (observed)
Historical trials
228
Completed
143
Terminated/Withdrawn
24
Completion rate
86%
Active now
58
Phase 2
85
Phase 3
122
Realized enrollment
278,779
First study year
2002
Years active
24
Match confidence
high
Enrollment velocity (inf)
11,616
Therapeutic
Areas
Cardiovascular, Metabolic (diabetes, obesity), Neurological, Respiratory, Primary Care, Rheumatology
Specialties
Diverse therapeutic areas (not enumerated)
Breadth (conditions)
195
Languages
Bilingual English/Spanish (coordinators)
States
FL (Miami-Dade, Broward, South Florida)
Recruitment (web observed)
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Limited
Capability notes
Hybrid model: dedicated facility + community physician practice network; diverse patient populations; South Florida demographic diversity (high Hispanic/Latino representation)
Relationships
Sponsors
Pfizer; Amgen; Hoffmann-La Roche; AbbVie; Eli Lilly and Company; Sanofi
CROs
IQVIA Pty Ltd; IQVIA Pvt. Ltd; Lexicon Pharmaceuticals; Medpace, Inc.; PPD Development, LP; Parexel
Owner / parent
Founded 2021; privately held; founder-led
Expansion
Y - South Florida network across Miami-Dade, Broward; 3,000 sq ft facility
Recent hiring
Y - founded 2021, building team
Capacity & people
Investigators
—
Coordinators
—
CEO
Jeffrey Somerstein (Founder & Site Director)
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
Unknown
Tech & DCT
eSource
Yes
Builds tech
Unknown
Home visits
Y - community physician practice network model
DCT / decentralized
Y - hybrid facility + distributed community practices model
Tech stack
Unknown
Recruiting visible
Unknown
Notes
Founder-led hybrid site + physician network; South Florida focus with diverse populations (FDA Diversity Action Plan opportunity); established 2021 (newer operator); direct decision-maker access; operational responsiveness. Limited scale (5-7 sites); single geographic region; newer organization with unproven track record. Recruitment-focused model but small footprint. [Validated: 5 active recruiting cardiometabolic trials on ClinicalTrials.gov.]
Recommendation features (sample indication)
Ind fit 1.00Liftability 0.71Overall70
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.